Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors

Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors

Background MEDI5395 is a recombinant attenuated Newcastle disease virus engineered to express a human granulocyte-macrophage colony-stimulating factor transgene. Preclinically, MEDI5395 demonstrated broad oncolytic activity, augmented by concomitant programmed cell death-1/programmed cell death liga...

Full description

Saved in:
Bibliographic Details
Main Authors: Dmitriy Zamarin, Diwakar Davar, Adel Samson, Kevin J Harrington, Siddharth Sheth, Eric Tu, Mitesh J Borad, Grace K Dy, Evanthia Galanis, Fernanda Arnaldez, Sandip P Patel, Nicholas Durham, Benedito A Carneiro, Sonia Agrawal, Zhongying Chen, Chunling Fan, Maozhen Gong, Jenny Burton, Kevin Laubscher
Format: Article
Language:English
Published: BMJ Publishing Group 2024-11-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/11/e009336.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/11/e009336.full

Similar Items